It is believed that sorafenib exerted a positive effect on pulmonary hypertension via the inhibition of pulmonary VEGFR2 and VEGF-A expression and the suppression of VEGF-A protein [140]. The gene discussed is KDR; the disease is pulmonary hypertension.